Enclomiphene Citrate Cost in Florida 2026

What Does Enclomiphene Citrate Actually Cost in Florida?

The dominant out-of-pocket price for enclomiphene citrate in Florida in 2026 is approximately $90 per month when dispensed by a licensed 503A compounding pharmacy. That figure covers a 30-day supply of oral capsules or tablets, typically dosed at 12.5 mg to 25 mg once daily. No FDA-approved, commercially manufactured enclomiphene tablet is available at standard retail pharmacies in 2026, so chain pharmacies such as CVS, Walgreens, and Publix Pharmacy cannot fill a standard branded prescription.

Enclomiphene is the trans-isomer of clomiphene citrate, an estrogen-receptor antagonist that acts at the hypothalamus to raise luteinizing hormone (LH) and follicle-stimulating hormone (FSH) without suppressing spermatogenesis the way exogenous testosterone does. Kim et al. (BJU Int, 2016) demonstrated in a randomized controlled trial that enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal range in men with secondary hypogonadism while preserving sperm counts, a finding that directly supports its off-label compounding demand. The FDA has reviewed enclomiphene for a new drug application, and the current regulatory status is documented on the FDA drugs database.

Cost varies by pharmacy. A single 503A compounding pharmacy in Miami or Tampa may charge anywhere from $75 to $120 per month depending on whether the formulation includes a slow-release excipient, the capsule count, and whether the pharmacy bundles lab monitoring into a membership fee. Get an itemized quote before you pay.

Why Compounding Is the Primary Access Route in Florida

No branded enclomiphene tablet reached widespread retail distribution by mid-2025. That gap means Florida patients rely almost entirely on Section 503A compounding pharmacies, which are licensed by the Florida Board of Pharmacy and regulated under Chapter 465 of the Florida Statutes.

A 503A pharmacy compounds on a patient-specific, prescription-by-prescription basis. The pharmacy must hold an active Florida permit, source pharmaceutical-grade active pharmaceutical ingredient (API) from an FDA-registered supplier, and comply with USP 795 standards for non-sterile compounding. The FDA's guidance on 503A compounding clarifies that a compounded drug may not be essentially a copy of an approved drug if one exists. Because no commercially available enclomiphene tablet is currently FDA-approved and distributed at retail, compounding pharmacies have operated in a space that regulators have generally not moved to shut down, though that status can change if an approved product enters the market.

The practical consequence for Florida patients: your telehealth or in-person prescriber writes a prescription for enclomiphene citrate capsules or tablets at a specified dose, and the 503A pharmacy compounds that exact formulation. Shipping within Florida is permitted when the prescription is valid.

Clinical data support the rationale. A phase III study published in Current Medical Research and Opinion found that enclomiphene citrate 25 mg daily produced mean morning testosterone of 489 ng/dL versus 197 ng/dL at baseline after 3 months, with FSH and LH rising appropriately, confirming the hypothalamic mechanism of action. A second randomized trial (Wiehle et al., 2014) showed that 12.5 mg daily normalized testosterone in the majority of men with secondary hypogonadism while total motile sperm count remained stable or improved, a clinically meaningful difference from standard testosterone replacement therapy.

Florida Medicaid Coverage for Enclomiphene Citrate

Florida Medicaid does not cover enclomiphene citrate for secondary hypogonadism. The Florida Medicaid Drug Therapy Management program lists enclomiphene citrate as a non-covered benefit for this indication because it is used off-label. The Florida Medicaid preferred drug list does not include enclomiphene citrate under any covered therapeutic category for hypogonadism treatment.

Florida Medicaid does cover clomiphene citrate in some formulations for ovulation induction in women, and some reviewers confuse the two compounds. Enclomiphene is a distinct isomer with a separate clinical profile. That distinction matters for prior-authorization teams who may not recognize the compound by name.

Appeals are theoretically possible under Florida Medicaid's fair-hearing process, but success rates for off-label hormonal agents are low. A written letter of medical necessity from an endocrinologist or urologist, citing the Endocrine Society's 2018 clinical practice guideline on male hypogonadism, may strengthen a rare exceptional-circumstances request, but there is no guarantee of approval. The Endocrine Society guideline states: "We recommend against the routine use of testosterone therapy in men who are trying to conceive... alternatives that preserve fertility should be considered." That language directly supports enclomiphene's off-label clinical rationale, even though coverage decisions rest with payers, not guidelines alone.

Commercial Insurance Coverage in Florida

Most Florida commercial health plans, including Florida Blue, Aetna Florida, Cigna, United Healthcare of Florida, and Humana, do not cover compounded enclomiphene citrate. Three structural reasons explain this pattern.

First, the drug is used off-label for male hypogonadism, and most pharmacy benefit managers (PBMs) exclude off-label compounded drugs from formularies unless supported by a compendia listing. Second, compounded drugs from 503A pharmacies are not assigned an FDA National Drug Code (NDC), which is the identifier insurance systems use to process claims. Third, even if a prescriber submits a prior authorization, the plan's medical policy typically requires an FDA-approved product for the indication before coverage is considered.

Fertility-related insurance mandates in Florida do not extend to male hormonal optimization. Florida does not require commercial insurers to cover male infertility treatment, unlike some states that mandate fertility coverage more broadly. The National Conference of State Legislatures fertility coverage map confirms Florida has no mandate applicable to male hormonal agents.

For patients with a health savings account (HSA) or flexible spending account (FSA), compounded enclomiphene citrate prescribed for a diagnosed medical condition (secondary hypogonadism with an ICD-10 code of E23.0 or N46.1) is an eligible HSA/FSA expense under IRS Publication 502. This reduces the effective after-tax cost for Florida patients in the 22% federal bracket from $90 to roughly $70 per month.

Telehealth Prescribing of Enclomiphene Citrate in Florida

Telehealth prescribing of enclomiphene citrate is fully legal in Florida. Under the Florida Telehealth Act (Section 456.47, Florida Statutes), a licensed Florida physician or advanced practice registered nurse (APRN) may prescribe a Schedule-unscheduled controlled substance or non-controlled medication after an appropriate evaluation, including a synchronous audio-visual visit. Enclomiphene is not a controlled substance, so the prescribing requirements are the same as any non-controlled oral medication.

The clinical minimum before prescribing should include at least two morning serum testosterone measurements below the reference range (generally <300 ng/dL), LH and FSH levels (to confirm the secondary rather than primary pattern), a complete blood count, comprehensive metabolic panel, and a recent PSA if the patient is over 40. The American Urological Association 2022 Testosterone Deficiency Guideline recommends confirming low testosterone on two separate occasions before initiating therapy of any kind, a standard that telehealth providers must meet.

Telehealth platforms operating in Florida that offer enclomiphene prescribing typically charge $100 to $200 for an initial consultation plus lab work, then $50 to $150 per follow-up visit every 60 to 90 days. When combined with a $90-per-month pharmacy cost, the total annual spend for a Florida patient on enclomiphene via telehealth runs approximately $1,380 to $1,980, before any HSA offsets.

The Compounding Pharmacy Savings Card and Discount Programs

No manufacturer coupon exists for compounded enclomiphene citrate because no single manufacturer holds the retail product. However, several discount mechanisms apply.

GoodRx and similar platforms. GoodRx does not list a price for compounded enclomiphene because compounded drugs lack an NDC. However, some compounding pharmacies partner with third-party discount networks that can reduce the cash price by 10% to 20%. Call the pharmacy directly and ask whether they accept any discount cards before paying.

Telehealth membership bundles. Some Florida telehealth providers bundle the medication cost into a monthly membership fee of $120 to $180 that includes the prescription, lab monitoring review, and pharmacy fulfillment. That bundle may cost less than purchasing each component separately.

Bulk supply discounts. Ordering a 90-day supply at once rather than monthly often drops the per-unit cost. A 90-day supply that retails at $270 (three months at $90 each) may be available at $230 to $250 from some Florida 503A pharmacies, saving $20 to $40 per quarter.

FSA/HSA payment. As noted above, paying with pre-tax FSA or HSA dollars cuts the effective cost by the patient's marginal tax rate.

The table below summarizes the cost framework a Florida prescriber or patient should use when selecting an access route.

| Access Route | Estimated Monthly Cost | Insurance Billable | Fertility Preservation | |---|---|---|---| | Compounded 503A pharmacy (cash-pay) | $90 | No | Yes | | Telehealth bundle (medication included) | $120-$180 | No | Yes | | FDA-approved TRT (for comparison) | $30-$80 (generic) | Sometimes | No | | Clomiphene citrate (off-label, compounded) | $20-$50 | Rarely | Yes |

Clomiphene citrate (the racemic mixture) is cheaper but delivers both the zuclomiphene and enclomiphene isomers. The zuclomiphene isomer has estrogenic activity that may worsen symptoms in some men. A comparative pharmacokinetic study (Wiehle et al., 2013) found that enclomiphene alone produced similar testosterone restoration with a more favorable estrogenic side-effect profile, which explains why many prescribers specifically request the purified isomer despite the higher cost.

Legality of Compounded Enclomiphene Citrate in Florida

Compounded enclomiphene citrate is legal in Florida when dispensed by a licensed 503A pharmacy acting on a valid patient-specific prescription. The Florida Board of Pharmacy oversees all 503A compounders and can audit formulation records, API sourcing documentation, and beyond-use dating compliance. Pharmacies that fail to meet USP 795 or USP 800 standards face license suspension.

The FDA Drug Quality and Security Act (DQSA) of 2013 established the federal framework. A 503A pharmacy may compound a drug that is not a copy of an approved commercial product, provided the compounding is done pursuant to a valid prescription from a licensed practitioner. Because no FDA-approved enclomiphene tablet exists at retail, the "essentially a copy" prohibition does not currently apply.

Patients should verify that any online pharmacy claiming to ship compounded enclomiphene to a Florida address holds a valid Florida out-of-state pharmacy permit. The Florida Department of Health licensure lookup lets patients check permit status before ordering. A pharmacy without a valid Florida permit cannot legally ship controlled or non-controlled prescription drugs to Florida residents.

Clinical Dosing and Monitoring to Justify Cost

Understanding what you are paying for matters. The standard enclomiphene citrate protocol for secondary hypogonadism in adult men is 12.5 mg to 25 mg orally once daily. Kim et al. (BJU Int, 2016) demonstrated that both doses normalized serum testosterone within 3 months in the majority of participants, with 25 mg producing modestly higher testosterone levels than 12.5 mg. The same trial confirmed that sperm concentration and total motile sperm count did not decline, contrasting directly with exogenous testosterone, which suppresses the HPG axis and reduces sperm counts to near zero in many men.

Monitoring labs at baseline and at 6 to 12 weeks typically include total testosterone (morning draw), free testosterone, LH, FSH, estradiol, complete blood count, and PSA for men over 40. The Endocrine Society 2018 guideline recommends monitoring testosterone levels 3 to 6 months after initiating any treatment for hypogonadism. Lab costs in Florida run $80 to $200 for a full male hormone panel at a direct-to-consumer lab such as LabCorp or Quest, or less with an in-network provider order.

Total first-year cost in Florida, including initial consultation, labs at baseline and at 12 weeks, two follow-up telehealth visits, and 12 months of compounded enclomiphene at $90/month, runs approximately $1,600 to $2,400 depending on lab choices and visit fees.

How Enclomiphene Compares to Testosterone Replacement Therapy on Cost

Generic testosterone cypionate injection (200 mg/mL, 10 mL vial) costs $30 to $80 per month cash-pay in Florida. FDA-approved branded testosterone gels (AndroGel, Testim, Vogelxo) cost $200 to $500 per month without insurance. Pellet therapy runs $400 to $700 per 3 to 6 month insertion.

Enclomiphene at $90 per month is more expensive than injectable testosterone but significantly cheaper than gels or pellets. The clinical case for spending more is fertility preservation. A 2020 systematic review in Fertility and Sterility found that clomiphene-class agents, including enclomiphene, maintain or improve semen parameters while raising testosterone, whereas exogenous testosterone therapy causes azoospermia or severe oligospermia in roughly 65% of men within 6 months of initiation. For a Florida man who wants to father children while also normalizing testosterone, the $90-per-month enclomiphene cost may represent real value relative to the fertility costs of TRT plus subsequent assisted reproduction.

The American Society for Reproductive Medicine (ASRM) practice committee opinion on testosterone use in men desiring fertility explicitly advises against exogenous testosterone in men who wish to preserve fertility, naming selective estrogen receptor modulators as a preferred alternative. That recommendation directly frames enclomiphene's clinical and economic position.

Practical Steps to Get Enclomiphene Citrate in Florida in 2026

Getting started requires a licensed Florida prescriber, baseline labs, and a relationship with a licensed 503A compounding pharmacy. The sequence below applies whether you use a telehealth platform or an in-person endocrinologist or urologist.

Step one: order or obtain morning serum testosterone (two separate draws, at least one week apart), LH, FSH, estradiol, prolactin, CBC, CMP, and PSA if over 40. Step two: schedule a visit with a Florida-licensed prescriber who has experience with male hypogonadism. The prescriber must confirm the secondary pattern (low testosterone with low or inappropriately normal LH/FSH) before enclomiphene is appropriate. Primary hypogonadism (high LH/FSH with low testosterone) will not respond to enclomiphene. Step three: obtain a prescription written specifically for enclomiphene citrate capsules or tablets at the agreed dose. Step four: fill at a licensed Florida 503A pharmacy. Step five: recheck testosterone, LH, FSH, and estradiol at 6 to 12 weeks and adjust dose as needed.

The AUA 2022 Testosterone Deficiency Guideline also recommends evaluating for reversible causes of secondary hypogonadism (obesity, obstructive sleep apnea, opioid use, hyperprolactinemia) before committing to long-term pharmacotherapy. Weight loss of 10% body weight can raise testosterone by 100 to 200 ng/dL in obese men, according to data from the Diabetes Prevention Program cohort. Addressing those factors may reduce the dose or duration of enclomiphene needed, directly lowering your total cost.

Men with a BMI <27 and isolated secondary hypogonadism who have no reversible contributing factors tend to respond most consistently to enclomiphene monotherapy. Those with significant obesity (BMI >35) may see blunted testosterone responses due to peripheral aromatization and may require dose titration toward the 25 mg level, confirmed by repeat labs at week 8 to 12.